T he risk of anal squamous cell carcinoma (SCC) is low in the general population. 1 A mild increase in this risk has been reported in patients with Crohn's disease in a meta-analysis of inflammatory bowel disease (IBD) referral center series, 2 possibly attributable to human papilloma virus (HPV) infection and chronic inflammation of anal mucosa. 3, 4 Patients with perianal fistulizing Crohn's disease are also at risk of perianal fistula-related SCC and adenocarcinoma. 5 Because anal and/or perianal Crohn's disease is associated in most cases with chronic inflammation of rectal mucosa, patients with chronic anal and/or perianal Crohn's disease also theoretically are at increased risk of rectal cancer. To date, the magnitude of these risks was unknown at a population level because IBD phenotype is missing in national registries and medico-administrative databases. We could specifically assess the risks of any malignancy in patients with anal and/or perianal Crohn's disease in the French nationwide Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales en France (CESAME) observational cohort because the presence of past or current anal and/or perianal lesions was noted at entry into the prospective observational period. In this study, we report the magnitude of the risk of anal and rectal cancer in the subgroup of patients with Crohn's perianal disease followed up in the CESAME observational cohort.
Methods

Experimental Design of the Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales en France Cohort
From May 2004 to June 2005, 680 French gastroenterologists (38.4% with a full-time hospital practice, 24.3% with a mixed public/private practice, and 37.3% with a full-time private practice) enrolled, on an unpaid basis, 19,486 consecutive IBD patients from their individual practices. There were no exclusion criteria.
Data were collected on an electronic case report form. The patients' demographic characteristics, IBD type, date of diagnosis, cumulative disease location (small bowel, colon [>50% or <50% of the total mucosal area affected, estimated from macroscopic or microscopic findings], or anus), previous history of cancer, and exposure to immune-suppressive therapy were recorded at the time of inclusion in the cohort. The gastroenterologists were asked to report all cases of high-grade dysplasia, cancer, or death among their patients during the follow-up period, and to provide information on each surviving patient, obtained during a final visit between January 1 and December 31, 2007. They also were asked to record all changes in immune-suppressive treatment status at interim visits. The follow-up period ended on December 31, 2007. Follow-up evaluation was complete (ie, included the final visit) in 16,459 cases (84.5%), partial (interim visits but no final visit) in 588 cases (3.0%), and nonexistent in 2439 cases (12.5%). The median followup period of the overall population was 35 months (interquartile range, 29-40 mo).
The protocol was approved by the institutional review boards of the French National Society of Gastroenterology, Association François Aupetit (the French IBD Patient Association), and Groupe d'Etude Thér-apeutique des Affections Inflammatoires du Tube Digestif. The study was authorized by the French Data Protection Agency (Commission Nationale de l'Informatique et des Libertés, registration number 04-1239, dated July 6, 2004) . The patients' specific written informed consent was not required for this observational study.
Characterization of the Cases of Anal Cancer and Rectal Cancer in Patients With Anal/Perianal Crohn's Disease
Clinical characteristics of patients with Crohn's disease and past or current anal and/or perianal lesions at entry into the observational period of the CESAME cohort, and which patients developed anal cancer or rectal high-grade dysplasia or rectal cancer during the follow-up period, were reviewed by a senior gastroenterologist (L.B.). Pathologic reports of biopsy and/or surgical specimens were reviewed jointly by a senior gastroenterologist (L.B.) and a senior pathologist (M.S.).
Statistical Analysis
To identify risk factors for anal cancer in the total CESAME population, we used a nested case-control (4 controls for 1 case) study matched for age and sex. We tested the following by univariate exact conditional regression: IBD subtype, disease duration, any exposure to immune-suppressive therapy at cohort entry, and the presence of past or current anal and/or perianal lesions at cohort entry.
Results
Demographics of the Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales en France Cohort
Of the 19,486 CESAME patients, 45.1% were male, 60.3% had Crohn's disease, and 39.7% had ulcerative colitis or IBD unclassified. Details of patient characteristics and exposure to various immune-suppressive drugs at cohort entry according to the IBD subtype are shown in Tables 1 and 2 . Most (83%) of the patients receiving any immune-suppressive drug were receiving thiopurines, either alone or in combination with anti-tumor necrosis factor agents in 90.2% and 9.8% of the cases, respectively. Among the 11,759 patients with Crohn's disease enrolled in the CESAME cohort, 2911 (24.8%) had previous or current anal and/or perianal lesions at entry into the observational period. In this subgroup, 1178 (40.5%) were males and the mean age of patients was 36.8 years (SD, 14.6 y). The mean disease duration from diagnosis to entry into the observational period was 10.6 years (SD, 2.1 y). No past or current involvement of rectum and colon at cohort entry was noted in 475 (16.3%) patients. An estimated cumulative proportion of mucosal colorectal area macroscopically or microscopically affected by IBD at cohort entry <50% or 50% was observed in 950 (32.6%) and 1486 (51.1%) patients, respectively. Among the 2911 patients with Crohn's disease and previous or current anal and/or perianal lesions at entry into the observational period, followed up for a total 7830 patient-years, 2 patients were diagnosed with anal SCC, 3 patients with perianal fistula-related anal adenocarcinoma, and 6 patients with rectal adenocarcinoma. Incidence rates ( Figure 1 ) were 0.26 per 1000 patient-years (95% CI, 0.03-0.92) for anal SCC, 0.38 per 1000 patient-years (95% CI, 0.08-1.12) for perianal fistula-related adenocarcinoma, and 0.77 per 1000 patient-years (95% CI, 0.28-1.67) for rectal adenocarcinoma (Table 3 ). The total incidence rate of anorectal cancers was 1.40 per 1000 patient-years (95% CI, 0.70-2.51). For the purpose of comparison between risk levels, the risk of colon cancer in patients with anal and/or perianal Crohn's disease (0.13 per 1000 patientyears; 95% CI, 0.003-0.711) also was plotted in Figure 1 . The remaining 16,575 individuals of the CESAME cohort population comprised 7727 patients with ulcerative colitis (n ¼ 7044) or IBD unclassified (n ¼ 683), and 8848 patients with Crohn's disease without previous or current anal or perianal lesions at entry into the observational period. In this population, 3 patients were diagnosed with anal SCC and 8 were diagnosed with rectal adenocarcinoma. Corresponding incidence rates were 0.08 per 1000 patient-years (95% CI, 0.02-0.23) and 0.21 per 1000 patient-years (95% CI, 0.09-0.42), respectively.
Characteristics of Cancers et
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Risk Factors for Anal Cancer in the Total Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales en France
To identify risk factors for anal cancer in the total CESAME population, we used a nested case-control (4 controls for 1 case) study matched for age and sex. Among the factors tested by univariate exact conditional regression (IBD subtype, disease duration, any exposure to immune-suppressive therapy at cohort entry, presence of past or current anal and/or perianal lesions at cohort entry), the presence of past or current anal and/ or perianal lesions at cohort entry was the sole factor significantly predictive for anal cancer (odds ratio, 11.2; 95% CI, 1.18-551.51; P ¼ .03).
Incidence of Anal or Rectal High-Grade Dysplasia
No case of incident anal high-grade dysplasia was reported in the CESAME population. Incident rates of Figure 1 . Incidence rates of anal squamous cell carcinoma, perianal fistula-related adenocarcinoma, rectal adenocarcinoma, and colon carcinoma in 2911 patients from the CESAME cohort with Crohn's disease and past or current anal and/or perianal lesions at entry into the observational period, followed up for 7830 patient-years. At entry into the observational period of the CESAME cohort. b Defined as IBD duration >10 years and an estimated cumulative proportion of mucosal area macroscopically or microscopically effected by IBD or 50%.
rectal high-grade dysplasia by IBD phenotype are indicated in Table 3 .
Incidence Rate Ratios of Anorectal Cancers in Patients With Crohn's Disease and Anal and/or Perianal Lesions
The incidence rate ratios of subtypes of anorectal cancers diagnosed in patients with Crohn's disease and anal and/or perianal lesions, compared with patients with Crohn's disease without anal or perianal lesions, and with patients with ulcerative colitis or IBD unclassified, are listed in Table 4 .
Characteristics of Incident Cases of Anal Cancer and Rectal High-Grade Dysplasia or Cancer in Patients With Crohn's Disease and Anal and/or Perianal Lesions
Ten of the 12 patients who developed anal or rectal high-grade dysplasia or cancer had active local mucosal inflammation at cancer diagnosis ( Table 5 ). The 9 patients who were diagnosed with perianal fistula-related adenocarcinoma (n ¼ 3) or rectal adenocarcinoma (n ¼ 6) during the follow-up period had a median age of 46 years at cancer diagnosis (range, 28-55 y), and a median disease duration of 14 years at cancer diagnosis (range, 9-26 y). One of the 3 patients diagnosed with perianal fistula-related adenocarcinoma had a rectovaginal fistula, and another patient had a pre-existing chronic anorectal stricture. The 3 patients diagnosed with perianal fistula-related adenocarcinoma had mucinous adenocarcinomas, defined according to the World Health Organization as tumors having pools of mucus with either disrupted tubules and/or interstitial mucus in more than 50% of the neoplasm. 6 This was also the case for 2 of the 6 cases of rectal adenocarcinoma.
Discussion
We estimated the risk of anal and rectal cancer in patients with Crohn's disease and anal and/or perianal lesions. We showed a high incidence rate of anorectal cancer, exceeding that of sporadic colorectal cancer in the general population 7 and in the total IBD population. 8, 9 Patients who develop perianal fistula-related or rectal adenocarcinoma are typically young patients with long-standing anorectal inflammation.
Our study had several limitations. The study population, defined as patients with any anal and/or perianal lesions from diagnosis of Crohn's disease to cohort entry, included patients with chronic anal and/or perianal lesions and patients with transient sporadic primary anal lesions or suppurative perianal lesions. Excluding these latter patients from analysis would lead to a higher incidence of cancers and reinforce the global alarming result of our study. Another limitation was that CESAME is a nationwide cohort, but not a population-based one. However, two thirds of the CESAME investigators were gastroenterologists with a partial or complete private practice, and the observed incidences of colorectal cancer in CESAME 8 were identical to those reported in the literature.
9,10 By contrast to previous CESAME studies on organ malignancies, 8, 11, 12 we could not provide standardized incidence ratios because in the French network of cancer registries, anal squamous cell carcinomas are pooled with skin cancers, and rectal cancers are not individualized among colorectal cancers. From a methodologic point of view, we acknowledge that the low absolute number of events in the study population may lead to imprecise estimates of incidence rate ratios. Finally, the mucosal HPV status of our patients was unknown and we were unable to address the role of smoking habits and family history of colorectal cancer because these data were not recorded at cohort entry. In the ongoing European cohort study Ibd CAncer and seRious infections in Europe (https://clinicaltrials.gov/ ct2/show/NCT02377258), these factors will be taken into account. We observed an incident rate of SCC higher than in the general population, 1 but close to that reported in meta-analyses in the Crohn's disease population. 2 This excess incidence is attributed to a conjunction of HPV infection and chronic local inflammation. 3, 4, 13 The resulting incidence remains low, but could be attenuated in the future by the impact of HPV vaccination, 14 and does not justify per se surveillance programs.
3 By contrast, the burden of anal cancers that are diagnosed in patients with Crohn's anal and/or perianal disease raises challenging questions of clinical practice. We also observed a high rate of rectal cancer in patients with anal and/or rectal Crohn's lesions, exceeding that observed in patients with ulcerative colitis at highest risk of colorectal cancer (ie, those with long-standing extensive colitis). 10 Overall, in patients with anal and/or perianal Crohn's disease, the risk of anorectal cancer was 11 times greater than the risk of colon cancer.
Thus, there is now a solid epidemiologic and pathogenesis rationale (dysplasia-cancer sequence in chronically inflamed lesions and fistula tracts) 15 for building surveillance programs to detect premalignant dysplastic lesions and early anorectal cancers in patients with longstanding anal and/or perianal Crohn's disease. At this time, optimal frequency and modalities of surveillance are unknown. 3, 16 In addition, the frequent presence of anorectal impassable strictures, 17 and initial location of malignant lesions in inaccessible fistula tracts make the surveillance difficult, if not, in some cases, impossible. 18, 19 Dedicated consensus and guidelines regarding the detection of advanced anorectal neoplasia in patients with anal and/or perianal Crohn's disease are now eagerly awaited.
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